ServiziMenu principaleHome

Partecipazioni dal 2001 al 2019

  • Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.
    The genomic grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. (BIG 1-98)
    JAMA Oncol 2:217-224, 2016.
  • EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.
    Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
    Lancet. 2014 Jun 21;383 (9935): 2127-35.
  • J Sven D Mieog, James P Morden, Judith M Bliss, R Charles Coombes, Cornelis J H van de Velde, on behalf of the IES Steering Committee
    Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Lancet Oncol 13: 420–32, 2012
  • LJ Fallowfield*,1, LS Kilburn2, C Langridge1, CF Snowdon2, JM Bliss2 and RC Coombes3 on behalf of the
    IES Trial Steering Committee
    Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.
    British Journal of Cancer 106, 1062 – 1067, 2012
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
    Lancet 378: 771-784, 2011 (IF=33.633)
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials
    Lancet 378: 1707-16, 2011 (IF=33.633)
  • Luca Gianni, Urania Dafni, Richard D Gelber, Evandro Azambuja, Susanne Muehlbauer, Aron Goldhirsch, Michael Untch, Ian Smith, José Baselga, Christian Jackisch, David Cameron, Max Mano, José Luiz Pedrini, Andrea Veronesi, Cesar Mendiola, Anna Pluzanska, Vladimir Semiglazov, Eduard Vrdoljak, Michael J Eckart, Zhenzhou Shen, George Skiadopoulos, Marion Procter, Kathleen I Pritchard, Martine J Piccart-Gebhart, and Richard Bell, for the Herceptin Adjuvant (HERA) Trial Study Team
    Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
    Lancet Oncol 2011; 12: 236–44
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast.
    J Natl Cancer Inst Monogr 41: 162–177, 2010. (IF=14.069)
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
    The Lancet 371: 29-40, 2008. (IF=30.758)
  • Lesley J. Fallowfield, Judith M. Bliss, Lucy S. Porter, Miranda H. Price, Claire F. Snowdon, Stephen E. Jones, R. Charles Coombes, and Emma Hall
    Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer.
    J Clin Oncol. 24 (6): 910-917, 2006. (IF=17.793)
  • Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE.
    Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
    J Clin Oncol. 24 (18): 2903-9, 2006. (IF=17.793)
  • Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer.
    Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    J Clin Oncol 22 (18): 3766-75, 2004. (IF=17.793)
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trial.
    Lancet 365: 1687-1717, 2005 (IF=30.758)
  • Zia MI, Siu LL, Pond GR, Chen EX.
    Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
    J Clin Oncol 23 (28): 6982-91, 2005. (IF=17.793)
  • Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y;
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
    Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
    Lancet 366: 2087-106, 2005. (IF=30.758)
  • Thurlimann B, Keshaviah A, Coates AS, et al;
    Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    N Engl J Med. 2005;353(26):2747-2757.
  • Carrick S, Ghersi D, Wilcken N, Simes J.
    Platinum containing regimens for metastatic breast cancer (Cochrane Review).
    In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
  • Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH.
    Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Annals of Oncology 15: 1330-8, 2004 (IF=5.647)
  • Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, Di Lorenzo G, Vernaglia Lombardi A, Signoriello G, Gallo C.
    Statistical design in phase II clinical trials and its application in breast cancer.
    Lancet Oncol 4: 305-311, 2003 (IF=14.470)
  • C.-H. Köhne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, B. Baron, F. Pignatti, P. Schöffski, S. Micheel and H. Hecker
    Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients
    Annals of Oncology 13:308-317, 2002 (IF=5.647)
  • Meta-Analysis Group in Cancer
    Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    British Journal of Cancer 84: 611-620, 2001 (IF=4.346)